Viridian Therapeutics, Inc.
VRDN· Nasdaq
VRDNViridian Therapeutics, Inc.
Filed Aug 14, 2014 · 10-Q · 45 days after period end · 0001171843-14-003982
| Metric | Q2 2014 | Q2 2013 |
|---|---|---|
| Revenue | $1.62M | $1.24M |
| Net Income | -$3.29M | -$629.69K |
| EPS Diluted | -$4.73 | -$3.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
ended Jun 30, 2014 · filed Aug 14, 2014 · 45 d after period end
